Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 May 1998

Evaluation of cross-reactive antiplatelet antibodies in whole blood by means of flow cytometry - limitations and pitfalls

Magdalena Boncler, Cezary Watała, Jacek Golański

Med Sci Monit 1998; 4(3): BR413-418 :: ID: 502397

Abstract

Platelet surface membrane alloantigens are believed to be the cause of alloimmunization phenomena following blood transfusions or due to antigenic immunocompetence between mother and fetus encountered in pregnant women. Under such conditions of incompatibility, alloimmunization can result in the resistance of donor platelets following blood transfusions. The advantage of flow cytometry in determining the occurrence of platelet alloantibodies (in comparison to other methods, like MAIPA) is that it is easy to perform with small aliquots of whole blood, the obtained results can be quantitatively evaluated and stored for later comparisons, and the technique can be also used in cases when platelet counts are low, such as in thrombocytopenias. The methods principle is that more alloantigenic or donor-incompatible platelets bind with more immunoglobulins in the recipient's plasma. Blood samples were incubated with FITC-labelled F(ab')2 antibodies, directed against IgG, adsorbed on the platelet's surface. Higher incompatibility resulted in the enhanced binding of F(ab')2-FITC antibodies. The attributed FITC-derived fluorescence, reflecting the extent to which platelets were coated with specific immunoglobulins, intensified along with the increasing immunoincompetence of the recipient's platelets and donor's plasma. Control values of the fluorescence ratio (FR = RFIF(ab')2-FITC: RFIIgGFITC) fluctuated between 1.08-1.77 (min-max), which corresponded to the normal range (mean±1SD) of 1.015-1.835. In other cases, the FR values for AB0-incompatible 'pairs' fluctuated between 1.75-3.26 which corresponded to the normal range (mean±1SD) of 1.606-3.464. The increase of FR above 1.75-1.85 may suggest a higher risk for serologic incompatibility and considerably downgrade successful blood transfusions.

Keywords: platelet surface antigens, platelet-reactive antibodies, platelet serology, Alloimmunization, alloantigenicity, Immunocompetence

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750